Table 1 Baseline characteristic of the validation cohort.
Baseline characteristics | Healthy controls (n = 100) | Patients without HCC (n = 100) | Patients with HCC (n = 100) | P |
|---|---|---|---|---|
Age (years) | 56.3 ± 3.4 | 56.7 ± 8.4 | 57.7 ± 8.6 | 0.053 |
Gender (Male) | 80 (80.0) | 85 (85.0) | 85 (85.0) | 0.549 |
Total bilirubin (mg/dL) |  | 0.9 ± 0.7 | 1.0 ± 0.7 | 0.729 |
Serum albumin (g/dL) |  | 4.1 ± 0.6 | 3.6 ± 0.5 |  < 0.001* |
Aspartate aminotransferase (IU/L) |  | 36.6 ± 30.2 | 64.5 ± 53.5 |  < 0.001* |
Alanine aminotransferase (IU/L) |  | 42.9 ± 42.3 | 44.8 ± 25.8 | 0.709 |
Alkaline phosphatase (IU/L) |  | 77.3 ± 50.6 | 125.3 ± 70.8 |  < 0.001* |
Platelet count (109/L) |  | 223.2 ± 74.6 | 176.0 ± 93.9 | 0.002* |
Alpha fetoprotein (ng/mL) |  | 8.5 ± 13.9 | 6928.1 ± 28,444.2 | 0.016* |
Presence of cirrhosis |  | 11 (11.0) | 80 (80.0) |  < 0.001* |
BCLC stage (0-A/B/C) | Â | - | 35(35.0)/50(50.0)/15(15.0) | - |
